Established as Platbio, Inc. in 2018, the KPC New Drug Development laboratory aspires to elevate global human health and establish South Korea as a leading hub in new drug development.

Since its inception, our laboratory has consistently focused on anti-cancer drug development, leveraging a state-of-the-art orthotopic model. This model enables precise evaluations of new drug efficacy and toxicity through direct tumor transplantation. Through these innovative methods, we’ve pinpointed over 50 specific targets, notably in pancreatic and ovarian cancers.

In a strategic maneuver in 2023 to lean more into “first-in-class drug development,” Platbio, Inc. merged with KPC.

Our esteemed team of researchers, boasting experience from the MD Anderson Cancer Center, bring unparalleled skills in utilizing the orthotopic model. Their adeptness in developing anti-cancer models closely mirroring patient tumor tissues significantly enhances the clinical translatability, thereby elevating the success rate of new drug development.

At KPC, our research prowess extends beyond in-house endeavors. We actively collaborate on novel drug development projects, fostering open innovation with other industry-leading companies.
We offer world-class animal experiments and pre-clinical evaluations, thereby enhancing the competitive edge of various bio-companies, especially those at pivotal pre-clinical or clinical stages.